|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hepatitis C | |||||
| Liver Cirrhosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Fibrosis | |||||
| Hepatitis | |||||
| Recurrence | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Disease Attributes | |||||
| Flaviviridae Infections | |||||
| Hepatitis, Viral, Human | |||||
| Liver Diseases | |||||
| Pathologic Processes | |||||
| RNA Virus Infections | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| tacrolimus + steroid | |||||
| tacrolimus + mycophenolate mofetil | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Mycophenolate mofetil | |||||
| Tacrolimus | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| Translational Research Informatics Center, Kobe, Hyogo, Japan | |||||
| Kyoto University | |||||